Addressing Critical U.S. Vulnerabilities in Vaccine Supply and National Preparedness ATLANTA, GA - January 29, 2025 ...

Process Expected to Increase Production Yield, Flexibility at Lower Cost ATLANTA, GA - January 27, 2025 (NEWMEDIAWIRE) - ...

GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing vaccines with a current market ...

GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial 15.01.2025 / 15:05 CET/CEST The issuer is solely responsible for the content of this announcement. Represents a Key Step Toward ...

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX – Get Free Report) have been given an average rating of “Buy” by the seven analysts ...

Completion of Enrollment in Booster Vaccine Study for Healthy Adult Volunteers GeoVax has successfully completed enrollment in its Phase 2 clinical trial evaluating GEO-CM04S1 as a booster vaccine ...

D. Boral Capital reissued their buy rating on shares of GeoVax Labs (NASDAQ:GOVX – Free Report) in a research report report published on Thursday,Benzinga reports. The firm currently has a $18.00 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide 27.01.2025 / 15:04 CET/CEST The issuer is solely responsible ...

Represents a Key Step Toward Validating Gedeptin Potential in Solid Tumor Therapy ATLANTA, GA - January 15, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...